Abstract
The effects of the long-acting beta 2-agonist salmeterol on early and late phase airways events provoked by inhaled allergen were assessed in a group of atopic asthmatic patients. In a placebo-controlled study, salmeterol 50 micrograms inhaled before allergen challenge ablated both the early and late phase of allergen-induced bronchoconstriction over a 34 h time period. Salmeterol also completely inhibited the allergen-induced rise in non-specific bronchial responsiveness over the same time period. These effects were shown to be unrelated to prolonged bronchodilatation or functional antagonism. These data suggest novel actions for topically active long-acting beta 2-agonists in asthma that extend beyond their protective action on airways smooth muscle.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Inhalation
-
Adrenergic beta-Agonists / administration & dosage
-
Adrenergic beta-Agonists / pharmacology
-
Adrenergic beta-Agonists / therapeutic use*
-
Adult
-
Albuterol / administration & dosage
-
Albuterol / analogs & derivatives*
-
Albuterol / pharmacology
-
Albuterol / therapeutic use
-
Analysis of Variance
-
Asthma / physiopathology
-
Asthma / prevention & control*
-
Bronchial Provocation Tests / methods
-
Bronchoconstriction / drug effects
-
Female
-
Forced Expiratory Volume / drug effects
-
Forced Expiratory Volume / physiology
-
Histamine / administration & dosage
-
Histamine / pharmacology
-
Humans
-
Male
-
Salmeterol Xinafoate
-
Time Factors
Substances
-
Adrenergic beta-Agonists
-
Salmeterol Xinafoate
-
Histamine
-
Albuterol